Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study.

Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO.

Eur J Haematol. 2018 Jun;100(6):613-620. doi: 10.1111/ejh.13057. Epub 2018 Apr 10.

PMID:
29532518
2.

Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011.

Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO.

Haematologica. 2017 Oct;102(10):1683-1690. doi: 10.3324/haematol.2017.169862. Epub 2017 Jul 27.

3.

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf Å, Garelius H, Lazarevic V, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M, Juliusson G.

Leukemia. 2017 Jun;31(6):1457-1459. doi: 10.1038/leu.2017.71. Epub 2017 Feb 24. No abstract available.

PMID:
28232742
4.

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf ÅR, Deneberg S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Lehmann S, Johansson B.

Eur J Haematol. 2017 May;98(5):493-500. doi: 10.1111/ejh.12861. Epub 2017 Mar 9.

PMID:
28152233
5.

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf Å, Garelius H, Lehmann S, Myhr-Eriksson K, Möllgård L, Uggla B, Wahlin A, Wennström L, Höglund M; Swedish AML Group and the Swedish Childhood Leukemia Group.

Leukemia. 2017 Mar;31(3):728-731. doi: 10.1038/leu.2016.312. Epub 2016 Oct 31. No abstract available.

6.

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.

Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf Å, Lehmann S, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Johansson B.

Am J Hematol. 2015 Sep;90(9):800-5. doi: 10.1002/ajh.24091. Epub 2015 Jul 22.

7.

Whole blood viscosity in plasma cell dyscrasias.

Uggla B, Nilsson TK.

Clin Biochem. 2015 Feb;48(3):122-4. doi: 10.1016/j.clinbiochem.2014.11.006. Epub 2014 Dec 16.

PMID:
25526882
8.

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.

Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G, Stockelberg D, Lehmann S.

Am J Hematol. 2015 Mar;90(3):208-14. doi: 10.1002/ajh.23908. Epub 2015 Jan 16.

9.

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.

Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf Å, Lehmann S, Möllgård L, Peterson S, Stockelberg D, Uggla B, Vennström L, Wahlin A, Höglund M, Juliusson G.

Eur J Haematol. 2015 May;94(5):419-23. doi: 10.1111/ejh.12446. Epub 2014 Oct 3.

PMID:
25200361
10.

Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.

Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G.

Blood Cancer J. 2014 Feb 28;4:e188. doi: 10.1038/bcj.2014.10.

11.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19.

PMID:
24554104
12.

Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.

Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg).

Leuk Lymphoma. 2014 Dec;55(12):2769-77. doi: 10.3109/10428194.2014.893306. Epub 2014 Apr 16.

PMID:
24524339
13.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
14.

Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab.

Ekbäck M, Uggla B.

Leuk Res. 2012 Aug;36(8):e190-1. doi: 10.1016/j.leukres.2012.04.016. Epub 2012 May 11. No abstract available.

PMID:
22579369
15.

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.

Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzén S, Nahi H, Uggla B, Tidefelt U, Höglund M, Paul C, Ekwall K, Döhner K, Lehmann S.

Blood. 2011 Nov 17;118(20):5573-82. doi: 10.1182/blood-2011-01-332353. Epub 2011 Sep 29.

16.

CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells.

Prenkert M, Uggla B, Tidefelt U, Strid H.

Anticancer Res. 2010 Oct;30(10):4157-61.

PMID:
21036735
17.

Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.

Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H.

Anticancer Res. 2009 Oct;29(10):4071-6.

18.

Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival.

Paul E, Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, Dahlman I, Rosenquist R, Wiman KG, Nahi H.

Leuk Lymphoma. 2009 Sep;50(9):1512-8. doi: 10.1080/10428190903111914.

PMID:
19626541
19.

Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.

Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A, Tidefelt U.

Int J Oncol. 2007 Jul;31(1):153-60.

PMID:
17549416
20.

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.

Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, Porwit-MacDonald A, Sjoo M, Tangen JM, Uggla B, Oberg G, Hellstrom-Lindberg E.

Haematologica. 2006 May;91(5):667-70.

21.

BCRP mRNA expression v. clinical outcome in 40 adult AML patients.

Uggla B, Ståhl E, Wågsäter D, Paul C, Karlsson MG, Sirsjö A, Tidefelt U.

Leuk Res. 2005 Feb;29(2):141-6.

PMID:
15607361
22.

Acquired hemophilia masked by warfarin therapy: report on two cases.

Uggla B, Linder O, Schulman S.

Blood Coagul Fibrinolysis. 2003 Dec;14(8):769-72.

PMID:
14614359
23.

Activation of granulocytes in patients treated with chemotherapy.

Uggla B, Tidefelt U, Vikerfors T, Fredlund H.

Clin Lab Haematol. 2002 Feb;24(1):29-31.

PMID:
11843895
24.

Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells.

Uggla B, Möllgård L, Ståhl E, Mossberg LL, Karlsson MG, Paul C, Tidefelt U.

Leuk Res. 2001 Nov;25(11):961-6.

PMID:
11597731

Supplemental Content

Support Center